UBS Lifts Target on Abbott Labs (ABT) Ahead of Split

UBS boosted its price target on Buy-rated Abbott Labs (NYSE: ABT) from $72 to $74, ahead of the finalizing of the its split on 12/31 after which the company will trade as two stocks.

"For New ABT, we model 3-yr rev & EBITDA growth of 5% & 9% w/ AbbVie at 4% & 4%. Notably, we expect ABT to provide details on NEWCO cap structures & divs over next 1-2 months."

For an analyst ratings summary and ratings history on Abbott Labs click here. For more ratings news on Abbott Labs click here.

Shares of Abbott Labs closed at $69.27 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wolfe Research Upgrades Abbott Labs (ABT) to Outperform
• Tencent Holdings (700:HK) (TCEHY) PT Lowered to HK$625 at Benchmark to Reflect Downward Earnings Revisions
• Yeti Holdings Inc. (YETI) PT Raised to $56 at Raymond James